Chimerix Story

<div class='circular--portrait' style='background:#FF0F00;color: #FFFFF0;font-size:4em;'>CH</div>
CMRX -- USA Stock  

USD 9.28  0.06  0.64%

As many millenniums are excited about healthcare space, it is only fair to break down Chimerix against current market trends. As expected, Chimerix is starting to reaffirm its true potential as investors are becoming more and more confident in the future outlook. The company returns are correlated to returns on the market. As market fluctuates, the company is expected to follow. Strong technical and fundamental indicators of the company may also suggest signals of long term gains for Chimerix investors. The upcoming quarterly report is expected on the 23rd of February 2021. The stock experiences an active upward rally.
Published over a week ago
View all stories for Chimerix | View All Stories
Planning to continue with Chimerix (NASDAQ:CMRX) in February?
Chimerix's average rating is Buy from 2 analysts. Do analysts base this consensus on technical analyses? We know that typical technical analysis utilizes price momentum, patterns, and trends looking at historical prices. It aims to identify signals based on Chimerix market sentiment investors' perception of the future value of Chimerix. Let us look at a few aspects of Chimerix technical analysis.
Using predictive technical analysis, we will analyze different prices and returns patterns and diagnose historical swings to determine the real value of Chimerix. In general, we focus on analyzing Chimerix stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Chimerix's daily price indicators and compare them against related drivers such as momentum indicators and various other types of predictive indicators. Using this methodology combined with a more conventional technical analysis and fundamental analysis, we attempt to find the most accurate representation of Chimerix's intrinsic value. In addition to deriving basic predictive indicators for Chimerix, we also check how macroeconomic factors affect Chimerix price patterns. Please read more on our technical analysis page or use our predictive modules below to complement your research.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Chimerix's stock price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Chimerix in the context of predictive analytics.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Chimerix. Your research has to be compared to or analyzed against Chimerix's peers to derive any actionable benefits. When done correctly, Chimerix's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Chimerix.

How does Chimerix Stands against Peers?

Analyzing Chimerix competition or peers my help you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Try to analyze the advantages of investing in traded instruments related to Chimerix across multiple sectors and thematic ideas. A good competitive analysis can cover a lot of different areas. But what areas to choose depends on who you are. The more exhaustive you are in your analysis, the more effective your competitive analysis will be.
Check out Chimerix Competition Details

How Chimerix utilizes its cash?

To perform a cash flow analysis of Chimerix, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Chimerix is receiving and how much cash it distributes out in a given period. The Chimerix cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Chimerix Net Cash Flow from Operations is fairly stable at the moment as compared to the past year. Chimerix reported Net Cash Flow from Operations of (67.66 Million) in 2020

Acquisition by David Jakeman of 1500 shares of Chimerix subject to Rule 16b-3

Legal trades by Chimerix insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Chimerix insider trading alert for grant of stock option (right to buy) by David Jakeman, Principal Accounting Officer, on 23rd of December 2020. This event was filed by Chimerix Inc with SEC on 2020-12-23. Statement of changes in beneficial ownership - SEC Form 4. David Jakeman currently serves as principal accounting officer, executive director of finance and accounting of Chimerix [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Closer look at Chimerix Semi Variance

Chimerix has current Semi Variance of 5.14. Semi-variance provides a good measure of downside volatility for equity or a portfolio. It is similar to variance, but it only looks at periods where the returns are less than the target or average level.

Semi-variance is the square of semi-deviation. Semi-variance is calculated by averaging the deviations of returns that have a result that is less than the mean.

Semi Variance 
 = 
SUM(RET DEV)2 
N(ZERO) 
 = 
5.14
SUM = Summation notation
RET DEV = Actual return deviation over selected period
N(ZERO) = Number of points with returns less than zero
Let's now compare Chimerix Semi Variance to its closest peers:
CMRX
EDIT
DRNA
EQ
DVAX
CMRX5.135338655688107
EDIT12.74
DRNA5.14
EQ38.34
DVAX23.0

Chimerix implied volatility may change after the rise

The jensen alpha is down to 1.04 as of today. Chimerix currently demonstrates below-verage downside deviation. It has Information Ratio of 0.18 and Jensen Alpha of 1.04. However, we do advice investors to further question Chimerix expected returns to ensure all indicators are consistent with the current outlook about its relatively low value at risk.

Our Conclusion on Chimerix

While some companies under the biotechnology industry are still a bit expensive, Chimerix may offer a potential longer-term growth to investors. The bottom line, as of the 8th of January 2021, our analysis shows that Chimerix almost mirrors the market. The company is undervalued and projects very low probability of distress for the next 2 years. Our final 30 days buy-sell recommendation on the company is Strong Buy.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of Chimerix. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com